Drug Type Contrast agent, Small molecule drug |
Synonyms PMI 03, PMI03 |
Target- |
Mechanism Magnetic resonance imaging enhancers |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Neuroinflammation | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Parkinson Disease | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Neurodegenerative Diseases | Phase 1 | US | 22 Aug 2019 | |
Inflammation | Phase 1 | US | 28 Jul 2019 | |
Nerve Degeneration | Phase 1 | - | - |